

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

HOLMES ET AL.

Examiner: Finn, Meghan R

APPLICATION NO: 10/516,633

FILED: JANUARY 19, 2005

FOR: THE USE OF SUBSTITUTED CYANOPYRROLIDINES AND
COMBINATION PREPARATIONS CONTAINING THEM FOR
TREATING HYPERLIPIDEMIA AND ASSOCIATED DISEASES

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450


FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,


Lisa M. Matovcik
Attorney for Applicants
Reg. No. 53,283

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 101
East Hanover, NJ 07936-1080
(862) 778-7831
Date: April 21, 2009

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1614

HOLMES ET AL.

Examiner: Finn, Meghan R

INTERNATIONAL APPLICATION NO: PCT/EP03/05762

FILED: 2 JUNE 2003

U.S. APPLICATION NO: 10/516,633

35 USC §371 DATE: 19 JANUARY 2005

FOR: THE USE OF SUBSTITUTED CYANOPYRROLIDINES AND
COMBINATION PREPARATIONS CONTAINING THEM FOR
TREATING HYPERLIPIDEMIA AND ASSOCIATED DISEASES

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the reference cited on the attached form(s) PTO-1449.

A copy of these reference is enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Lisa M. Matovcik
Attorney for Applicants
Reg. No. 53,283

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 101
East Hanover, NJ 07936-1080
(862) 778-9308

Date: April 21, 2009